Early miR-223 Upregulation in Gastroesophageal Carcinogenesis

Matteo Fassan, Deborah Saraggi, Laura Balsamo, Stefano Realdon, Marco Scarpa, Carlo Castoro, Irene Coati, Roberta Salmaso, Fabio Farinati, Vincenza Guzzardo, Diletta Arcidiacono, Giada Munari, Pierluigi Gasparini, Nicola Veronese, Claudio Luchini, Nicola Valeri, Massimo Rugge

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: To test miR-223 upregulation during gastric (intestinal-type) and Barrett esophageal carcinogenesis. Methods: miR-223 expression was assessed by quantitative reverse transcription polymerase chain reaction in a series of 280 gastroesophageal biopsy samples representative of the whole spectrum of phenotypic changes involved in both carcinogenetic cascades. The results were further validated by in situ hybridization on multiple tissue specimens obtained from six surgically treated gastroesophageal adenocarcinomas. miR-223 expression was also assessed in plasma samples from 30 patients with early stage (ie, stages I and II) gastroesophageal adenocarcinoma and relative controls. Results: In both gastric and esophageal models, miR-223 expression significantly increased along with the severity of the considered lesions (analysis of variance, P <.001). Among atrophic gastritis and long-segment Barrett esophagus samples, miR-223 overexpression was significantly associated with the score of intestinal metaplasia. miR-223 plasma levels were significantly upregulated in patients with cancer compared with controls (t test, both P <.001). Conclusions: miR-223 early upregulation observed in tissue samples and its diagnostic value in discriminating patients with early adenocarcinoma by plasma testing provide a solid rationale for further exploring the diagnostic reliability of this microRNA as a novel biomarker in gastroesophageal adenocarcinoma secondary prevention strategies.

Original languageEnglish
Pages (from-to)301-308
Number of pages8
JournalAmerican Journal of Clinical Pathology
Volume147
Issue number3
DOIs
Publication statusPublished - Mar 1 2017

Fingerprint

Carcinogenesis
Adenocarcinoma
Up-Regulation
Stomach
Atrophic Gastritis
Barrett Esophagus
Metaplasia
Secondary Prevention
MicroRNAs
Reverse Transcription
In Situ Hybridization
Analysis of Variance
Biomarkers
Biopsy
Polymerase Chain Reaction
Neoplasms

Keywords

  • barrett carcinogenesis
  • gastric adenocarcinoma
  • microRNA
  • preneoplastic lesions

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Early miR-223 Upregulation in Gastroesophageal Carcinogenesis. / Fassan, Matteo; Saraggi, Deborah; Balsamo, Laura; Realdon, Stefano; Scarpa, Marco; Castoro, Carlo; Coati, Irene; Salmaso, Roberta; Farinati, Fabio; Guzzardo, Vincenza; Arcidiacono, Diletta; Munari, Giada; Gasparini, Pierluigi; Veronese, Nicola; Luchini, Claudio; Valeri, Nicola; Rugge, Massimo.

In: American Journal of Clinical Pathology, Vol. 147, No. 3, 01.03.2017, p. 301-308.

Research output: Contribution to journalArticle

Fassan, M, Saraggi, D, Balsamo, L, Realdon, S, Scarpa, M, Castoro, C, Coati, I, Salmaso, R, Farinati, F, Guzzardo, V, Arcidiacono, D, Munari, G, Gasparini, P, Veronese, N, Luchini, C, Valeri, N & Rugge, M 2017, 'Early miR-223 Upregulation in Gastroesophageal Carcinogenesis', American Journal of Clinical Pathology, vol. 147, no. 3, pp. 301-308. https://doi.org/10.1093/ajcp/aqx004
Fassan, Matteo ; Saraggi, Deborah ; Balsamo, Laura ; Realdon, Stefano ; Scarpa, Marco ; Castoro, Carlo ; Coati, Irene ; Salmaso, Roberta ; Farinati, Fabio ; Guzzardo, Vincenza ; Arcidiacono, Diletta ; Munari, Giada ; Gasparini, Pierluigi ; Veronese, Nicola ; Luchini, Claudio ; Valeri, Nicola ; Rugge, Massimo. / Early miR-223 Upregulation in Gastroesophageal Carcinogenesis. In: American Journal of Clinical Pathology. 2017 ; Vol. 147, No. 3. pp. 301-308.
@article{f37480042ff5404eb6e2601839440490,
title = "Early miR-223 Upregulation in Gastroesophageal Carcinogenesis",
abstract = "Objectives: To test miR-223 upregulation during gastric (intestinal-type) and Barrett esophageal carcinogenesis. Methods: miR-223 expression was assessed by quantitative reverse transcription polymerase chain reaction in a series of 280 gastroesophageal biopsy samples representative of the whole spectrum of phenotypic changes involved in both carcinogenetic cascades. The results were further validated by in situ hybridization on multiple tissue specimens obtained from six surgically treated gastroesophageal adenocarcinomas. miR-223 expression was also assessed in plasma samples from 30 patients with early stage (ie, stages I and II) gastroesophageal adenocarcinoma and relative controls. Results: In both gastric and esophageal models, miR-223 expression significantly increased along with the severity of the considered lesions (analysis of variance, P <.001). Among atrophic gastritis and long-segment Barrett esophagus samples, miR-223 overexpression was significantly associated with the score of intestinal metaplasia. miR-223 plasma levels were significantly upregulated in patients with cancer compared with controls (t test, both P <.001). Conclusions: miR-223 early upregulation observed in tissue samples and its diagnostic value in discriminating patients with early adenocarcinoma by plasma testing provide a solid rationale for further exploring the diagnostic reliability of this microRNA as a novel biomarker in gastroesophageal adenocarcinoma secondary prevention strategies.",
keywords = "barrett carcinogenesis, gastric adenocarcinoma, microRNA, preneoplastic lesions",
author = "Matteo Fassan and Deborah Saraggi and Laura Balsamo and Stefano Realdon and Marco Scarpa and Carlo Castoro and Irene Coati and Roberta Salmaso and Fabio Farinati and Vincenza Guzzardo and Diletta Arcidiacono and Giada Munari and Pierluigi Gasparini and Nicola Veronese and Claudio Luchini and Nicola Valeri and Massimo Rugge",
year = "2017",
month = "3",
day = "1",
doi = "10.1093/ajcp/aqx004",
language = "English",
volume = "147",
pages = "301--308",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - Early miR-223 Upregulation in Gastroesophageal Carcinogenesis

AU - Fassan, Matteo

AU - Saraggi, Deborah

AU - Balsamo, Laura

AU - Realdon, Stefano

AU - Scarpa, Marco

AU - Castoro, Carlo

AU - Coati, Irene

AU - Salmaso, Roberta

AU - Farinati, Fabio

AU - Guzzardo, Vincenza

AU - Arcidiacono, Diletta

AU - Munari, Giada

AU - Gasparini, Pierluigi

AU - Veronese, Nicola

AU - Luchini, Claudio

AU - Valeri, Nicola

AU - Rugge, Massimo

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Objectives: To test miR-223 upregulation during gastric (intestinal-type) and Barrett esophageal carcinogenesis. Methods: miR-223 expression was assessed by quantitative reverse transcription polymerase chain reaction in a series of 280 gastroesophageal biopsy samples representative of the whole spectrum of phenotypic changes involved in both carcinogenetic cascades. The results were further validated by in situ hybridization on multiple tissue specimens obtained from six surgically treated gastroesophageal adenocarcinomas. miR-223 expression was also assessed in plasma samples from 30 patients with early stage (ie, stages I and II) gastroesophageal adenocarcinoma and relative controls. Results: In both gastric and esophageal models, miR-223 expression significantly increased along with the severity of the considered lesions (analysis of variance, P <.001). Among atrophic gastritis and long-segment Barrett esophagus samples, miR-223 overexpression was significantly associated with the score of intestinal metaplasia. miR-223 plasma levels were significantly upregulated in patients with cancer compared with controls (t test, both P <.001). Conclusions: miR-223 early upregulation observed in tissue samples and its diagnostic value in discriminating patients with early adenocarcinoma by plasma testing provide a solid rationale for further exploring the diagnostic reliability of this microRNA as a novel biomarker in gastroesophageal adenocarcinoma secondary prevention strategies.

AB - Objectives: To test miR-223 upregulation during gastric (intestinal-type) and Barrett esophageal carcinogenesis. Methods: miR-223 expression was assessed by quantitative reverse transcription polymerase chain reaction in a series of 280 gastroesophageal biopsy samples representative of the whole spectrum of phenotypic changes involved in both carcinogenetic cascades. The results were further validated by in situ hybridization on multiple tissue specimens obtained from six surgically treated gastroesophageal adenocarcinomas. miR-223 expression was also assessed in plasma samples from 30 patients with early stage (ie, stages I and II) gastroesophageal adenocarcinoma and relative controls. Results: In both gastric and esophageal models, miR-223 expression significantly increased along with the severity of the considered lesions (analysis of variance, P <.001). Among atrophic gastritis and long-segment Barrett esophagus samples, miR-223 overexpression was significantly associated with the score of intestinal metaplasia. miR-223 plasma levels were significantly upregulated in patients with cancer compared with controls (t test, both P <.001). Conclusions: miR-223 early upregulation observed in tissue samples and its diagnostic value in discriminating patients with early adenocarcinoma by plasma testing provide a solid rationale for further exploring the diagnostic reliability of this microRNA as a novel biomarker in gastroesophageal adenocarcinoma secondary prevention strategies.

KW - barrett carcinogenesis

KW - gastric adenocarcinoma

KW - microRNA

KW - preneoplastic lesions

UR - http://www.scopus.com/inward/record.url?scp=85017484422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017484422&partnerID=8YFLogxK

U2 - 10.1093/ajcp/aqx004

DO - 10.1093/ajcp/aqx004

M3 - Article

VL - 147

SP - 301

EP - 308

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -